DMDevon Muir

Devon Muir

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Devon Muir has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Atypical hepatitis B surface antigen escape mutations in an HIV-positive patient in South Africa

    by Menzi B. Nkosi, Marije van Schalkwyk, Tongai G. Maponga, Yoliswa Z. Chili, Devon Muir, Paula R. Delport, Susan S. Hugo, Zahiera Ismail, Jantjie Taljaard, Gert U. van Zyl, et al.

    A 44-year-old woman with human immunodeficiency virus (HIV), chronic kidney disease and chronic diarrhoea presented with worsening gastrointestinal symptoms and renal impairment. Despite reported adherence, she had HIV viraemia and atypical hepatitis B serology (absence of hepatitis B core antibody and co-existence of hepatitis B surface antigen (HBsAg) and hepatitis B surface antibody) with high hepatitis B virus DNA. Whole genome sequencing of hepatitis B virus was performed using Oxford Nanopore Technologies sequencing on the Oxford Nanopore Technologies GridION (ONT, Oxford, United Kingdom). Genotype A infection with HBsAg immune escape mutations D144G/G145E was identified, without drug-resistance mutations. Contribution: Findings are most consistent with hepatitis B virus reactivation following prior natural infection and subsequent loss of immune control.

  • Open Access

    Hepatitis B seroprevalence among HIV-positive adults in the Free State, South Africa

    by Devon Muir, Sabeehah Vawda, Phillip A. Bester, Cornel van Rooyen, Dominique Goedhals

    Background: HIV and hepatitis B virus (HBV) coinfection impacts negatively on the prognosis for people living with HIV (PLHIV). HBV is relatively neglected compared to HIV in the South African setting, with limited coinfection seroprevalence data from the Free State. Objectives: This study aimed to determine the seroprevalence of current and previous HBV in PLHIV in the Free State, South Africa. Method: In this descriptive cross-sectional study, 1007 residual HIV viral load (VL) samples were selected and screened for markers of current HBV infection (hepatitis B surface antigen [HBsAg]) and previous exposure to HBV (total antibodies to hepatitis B core antigen [HBcTA]) between 01 February 2022 and 31 March 2022. Seroprevalence was assessed for municipal health districts, age, sex, and HIV VL categories. Results: HBsAg seroprevalence was 6.26% and HBcTA seroprevalence was 36.05%. HBsAg seroprevalence was significantly higher in men at 8.12% as compared to women at 4.38% (P = 0.014). HBcTA seropositivity was also higher in men than in women, at 42.97% for men and 29.08% for women (P < 0.0001). Peak HBsAg and HBcTA positivity was observed among the 40–59-year age group in both men and women. No significant difference was found in HBV seroprevalence and exposure between districts or HIV VL categories. Conclusion: These findings demonstrate that PLHIV in the Free State, South Africa, fall under the intermediate HBV prevalence category. HBV infection remains a public health concern and emphasis should be placed on identifying and addressing programmatic gaps regarding diagnosis and management.